Clinical Trial Update: 5 Day Versus 7 Day Azacitidine in Lower Risk Myelodysplastic Syndrome [Phase 2]

View source ↗

Summary

This clinical trial update reports on a Phase 2 study comparing 5-day versus 7-day azacitidine in lower-risk myelodysplastic syndrome. The current status of the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• AZACITIDINE (AZACITIDINE)

Snippet

Sponsor: Seoul St. Mary's Hospital | Conditions: Myelodysplastic Syndrome | Phase 2 | Status: UNKNOWN